Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.
Background This study examined employment patterns and associated factors in lymphoma survivors treated with high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT) from diagnosis to a follow-up survey at a mean of 10 years after HDT-ASCT. Patients and methods All lymphoma survivors aged ≥18 years at HDT-ASCT in Norway from 1987 to 2008, and alive at the end of 2011 were eligible for this cross-sectional study performed in 2012/2013. Participants completed a mailed questionnaire. Job status was dichotomized as either employed (paid work) or not-employed (disability and retirement pension, on economic support, home-makers, or students). Results The response rate was 78%, and the sample (N = 312) contained 60% men. Mean age at HDT-ASCT was 44.3 and at survey 54.0 years. At diagnosis 85% of survivors were employed, 77% before and 77% after HDT-ASCT, and 58% at follow-up. Forty seven percent of the survivors were employed at all time points. The not-employed group at survey was significantly older and included significantly more females than the employed group. No significant between-group differences were observed for lymphoma-related variables. Fatigue, mental distress and type D personality were significantly higher among those not-employed, while quality of life was significantly lower compared to the employed group. Older age at survey, being female, work ability and presence of type D personality remained significantly related to being not-employed at survey in the multivariable analysis. Conclusions Our findings show that not-employed long-term survivors after HDT-ASCT for lymphoma have more comorbidity, cognitive problems and higher levels of anxiety/depression than employed survivors. These factors should be checked and eventually treated in order to improve work ability.
a National Advisory Unit for Late Effects After Cancer, Department of Oncology , Oslo University Hospital, Radiumhospitalet , Oslo , Norway ;
C E
CE
Kiserud
b Department of Oncology , St. Olav's Hospital , Trondheim , Norway ;|c Department of Cancer Research and Molecular Medicine , Norwegian University of Science and Technology , Trondheim , Norway ;
U-M
UM
Fagerli
a National Advisory Unit for Late Effects After Cancer, Department of Oncology , Oslo University Hospital, Radiumhospitalet , Oslo , Norway ;|d Faculty of Medicine, University of Oslo , Oslo , Norway ;
K B
KB
Smeland
e Department of Oncology , Haukeland University Hospital , Bergen , Norway ;
Ø
Ø
Fluge
f Department of Oncology , University Hospital of North Norway , Tromsø , Norway.
H
H
Bersvendsen
a National Advisory Unit for Late Effects After Cancer, Department of Oncology , Oslo University Hospital, Radiumhospitalet , Oslo , Norway ;|d Faculty of Medicine, University of Oslo , Oslo , Norway ;
S
S
Kvaløy
a National Advisory Unit for Late Effects After Cancer, Department of Oncology , Oslo University Hospital, Radiumhospitalet , Oslo , Norway ;
H
H
Holte
a National Advisory Unit for Late Effects After Cancer, Department of Oncology , Oslo University Hospital, Radiumhospitalet , Oslo , Norway ;|d Faculty of Medicine, University of Oslo , Oslo , Norway ;
A A
AA
Dahl
D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015897:Comorbidity; D003430:Cross-Sectional Studies; D004651:Employment / Q000706:statistics & numerical data*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma / Q000453:epidemiology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D011788:Quality of Life; D012189:Retrospective Studies; D012737:Sex Factors; D033581:Stem Cell Transplantation; D011795:Surveys and Questionnaires; D017741:Survivors / Q000523:psychology / Q000706:statistics & numerical data*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014478:Unemployment / Q000706:statistics & numerical data
D000970:Antineoplastic Agents